Custom vectors for treating and preventing pancreatic cancer
The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).
1. A method for inducing an immunological response against malignant pancreatic cells in an individual, wherein the method comprises:
(a) selecting an individual having malignant pancreatic cells,
(b) administering to the individual a first poxvirus vector comprising SEQ ID NO: 1 and SEQ ID NO: 3 and DNA sequences encoding ICAM-1, LFA-3, and B7.1, and
(c) at regular intervals thereafter administering at least a second poxvirus vector comprising SEQ ID NO: 1 and SEQ ID NO: 3 and DNA sequences encoding ICAM-1, LFA-3, and B7.1,
such that an immunological response against the malignant pancreatic cells is induced in the individual.
2. The method according to claim 1 , wherein the first and second poxvirus vectors are selected from the group consisting of an orthopox virus vector; avipox virus vector; a suipox virus vector; a capripox virus vector; a leporipox virus vector; and an iridovirus vector.
3. The method according to claim 1 , wherein the first poxvirus vector, the second poxvirus vector, or both the first and the second poxvirus vectors is a replication impaired or non-replicating poxvirus vector.
4. The method according to claim 3 , wherein the first poxvirus vector, the second poxvirus vector, or both the first and the second poxvirus vectors is an orthopox vector.
5. The method according to claim 4 , wherein the orthopox virus vector is vaccinia.
6. The method of claim 1 , wherein the first poxvirus vector is an orthopox vector, and the second poxvirus vector is an avipox vector.
7. The method of claim 6 , wherein the orthopox vector is vaccinia.
8. The method of claim 7 , wherein the vaccinia is an attenuated vaccinia.
9. The method of claim 8 , wherein the attenuated vaccinia is MVA or NYVAC.
10. The method of claim 6 , wherein the orthopox vector is administered in one to three administrations at set intervals, and the avipox vector is administered in multiple administrations at set intervals.
11. The method of claim 10 , wherein the set interval is 20 days to 90 days.
12. The method of claim 1 , wherein the immunological response against a malignant pancreatic cell is a cell-mediated immune response.
13. The method of claim 12 , wherein the cell-mediated immune response is against malignant pancreatic cells expressing CEA and MUC.
14. A method of inhibiting growth of malignant pancreatic cells in an individual, wherein the method comprises:
(a) selecting an individual having malignant pancreatic cells,
(b) administering to the individual a first poxvirus vector comprising SEQ ID NO: 1 and SEQ ID NO: 3 and DNA sequences encoding ICAM-1, LFA-3, and B7.1, and
(c) at regular intervals thereafter administering at least a second poxvirus vector comprising SEQ ID NO: 1 and SEQ ID NO: 3 and DNA sequences encoding ICAM-1, LFA-3, and B7.1,
such that the growth of the malignant pancreatic cells is inhibited in the individual.
15. The method according to claim 14 , wherein the first and second poxvirus vectors are selected from the group consisting of an orthopox virus vector; avipox virus vector; a suipox virus vector; a capripox virus vector; a leporipox virus vector; and an iridovirus vector.
16. The method according to claim 14 , wherein the first poxvirus vector, the second poxvirus vector, or both the first and the second poxvirus vectors is a replication impaired or non-replicating poxvirus vector.
17. The method according to claim 16 , wherein the first poxvirus vector, the second poxvirus vector, or both the first and the second poxvirus vectors is an orthopox vector.
18. The method according to claim 17 , wherein the orthopox virus vector is vaccinia.
19. The method of claim 14 , wherein the first poxvirus vector is an orthopox vector, and the second poxvirus vector is an avipox vector.
20. The method of claim 19 , wherein the orthopox vector is vaccinia.
21. The method of claim 20 , wherein the vaccinia is an attenuated vaccinia.
22. The method of claim 21 , wherein the attenuated vaccinia is MVA or NYVAC.
23. The method of claim 19 , wherein the orthopox vector is administered in one to three administrations at set intervals, and the avipox vector is administered in multiple administrations at set intervals.
24. The method of claim 23 , wherein the set interval is 20 days to 90 days.